The Best Company for Investing in the Diabetes Market
Diabetes spending is growing rapidly, and this company is the best way for investors to capitalize on the trend.
Here's Why MannKind Corporation Was Clobbered in April
The drubbing continued in April for MannKind, with its shares dipping another 18%. Find out why investors fled for the hills once again, and whether this pessimism is truly warranted.
It's Partners and Pipeline Before Bean Counting at Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals highlights its new partnerships while continuing to shrug off sales of its approved drug, Kynamro.